source
- EMA releases updated guidance on drug shortage prevention plansThe European Medicines Agency has published a revised guideline aimed at helping marketing authorisation holders develop and keep drug shortage prevention plans for their products. The new guidanc…
- BioMarin halts development of BMN401 enzyme therapy after mixed Phase 3 resultsBioMarin announced it will stop work on BMN401, an enzyme replacement therapy aimed at treating ENPP1 deficiency, a rare genetic disorder. The decision follows a Phase 3 trial that produced mixed…